5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 17 points (-0.1%) at 12,949 as of Tuesday, Nov. 27, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,707 issues advancing vs. 1,183 declining with 148 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.0%. A company within the industry that fell today was Life Technologies ( LIFE), up 1.0%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Services industry lower today. As of noon trading, DaVita HealthCare Partners is down $0.84 (-0.8%) to $109.16 on heavy volume Thus far, 661,966 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 868,400 shares. The stock has ranged in price between $108.84-$110.42 after having opened the day at $110.18 as compared to the previous trading day's close of $110.00.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $10.6 billion and is part of the health care sector. The company has a P/E ratio of 20.2, above the S&P 500 P/E ratio of 17.7. Shares are up 47.0% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full DaVita HealthCare Partners Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

4. As of noon trading, Humana ( HUM) is down $0.72 (-1.1%) to $65.40 on average volume Thus far, 756,326 shares of Humana exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $65.22-$66.30 after having opened the day at $65.78 as compared to the previous trading day's close of $66.12.

Humana Inc. operates as a health care company that offers a range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. Humana has a market cap of $10.6 billion and is part of the health care sector. The company has a P/E ratio of 8.9, below the S&P 500 P/E ratio of 17.7. Shares are down 23.9% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Humana a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Humana Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

3. As of noon trading, Intuitive Surgical ( ISRG) is down $7.74 (-1.4%) to $526.51 on light volume Thus far, 87,451 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 353,900 shares. The stock has ranged in price between $525.92-$534.63 after having opened the day at $532.21 as compared to the previous trading day's close of $534.25.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems for various surgical procedures, including urologic, gynecologic, cardiothoracic, general, and head and neck surgeries. Intuitive Surgical has a market cap of $21.4 billion and is part of the health care sector. The company has a P/E ratio of 34.7, above the S&P 500 P/E ratio of 17.7. Shares are up 15.4% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Intuitive Surgical a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Intuitive Surgical Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

2. As of noon trading, Baxter International ( BAX) is down $0.70 (-1.1%) to $66.14 on light volume Thus far, 1.1 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $65.90-$66.74 after having opened the day at $66.50 as compared to the previous trading day's close of $66.84.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.7 billion and is part of the health care sector. The company has a P/E ratio of 16.7, below the S&P 500 P/E ratio of 17.7. Shares are up 39.1% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Baxter International a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Baxter International Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

1. As of noon trading, UnitedHealth Group ( UNH) is down $0.34 (-0.6%) to $53.19 on light volume Thus far, 2.1 million shares of UnitedHealth Group exchanged hands as compared to its average daily volume of 6.0 million shares. The stock has ranged in price between $52.97-$53.83 after having opened the day at $53.12 as compared to the previous trading day's close of $53.53.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. UnitedHealth Group has a market cap of $55.1 billion and is part of the health care sector. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 6.4% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate UnitedHealth Group a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates UnitedHealth Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full UnitedHealth Group Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing